Jonathan(Jon ) Hollick
Seminars
Wednesday 28th January 2026
Targeting Polθ’s Dual Domains to Guide Candidate Selection & Strategic Partnering
11:00 am
• See how Breakpoint Therapeutics is guiding candidate selection by comparing helicase vs. polymerase inhibition to inform domain targeting
• Presenting Breakpoint’s candidate molecule and second-generation compound with updated preclinical efficacy and safety data
• Contextualizing Breakpoint’s program within the broader Polθ landscape to highlight differentiation and partnering potential
Thursday 29th January 2026
Panel: Uniting Founders and Funders to Align Scientific Vision with Investment Strategy
9:30 am
• Bringing together academic founders and investors to explore what makes DDR programs fundable
• Examining licensing, MTA bottlenecks, and funding models across early and late-stage ventures
• Offering insights into risk assessment, strategic partnerships, and scaling innovation
